Previous 10 | Next 10 |
home / stock / fh:cc / fh:cc news
FILAMENT HEALTH ANNOUNCES PSILOCYBIN SUPPLY AGREEMENT WITH THE CENTRE FOR ADDICTION AND MENTAL HEALTH Canada NewsWire CAMH to use Filament's natural psilocybin drug candidate for a clinical trial studying treatment-resistant depression VANCOUVER, BC , ...
FILAMENT HEALTH ANNOUNCES THIRD QUARTER 2022 FINANCIAL RESULTS AND OPERATIONAL HIGHLIGHTS Canada NewsWire VANCOUVER, BC , Nov. 10, 2022 /CNW/ - Filament Health Corp. (OTCQB: FLHLF) (NEO: FH) (FSE: 7QS) ("Filament" or the "Company"), a clinical-sta...
FILAMENT HEALTH TO HOST VIRTUAL INVESTOR UPDATE Canada NewsWire Attendees will gain insight into the Company's clinical trials, partnership network, and growth plans VANCOUVER, BC , Oct. 12, 2022 /CNW/ - Filament Health Corp. (OTCQB: ...
TORONTO, Sept. 22, 2022 (GLOBE NEWSWIRE) -- Psyence Group Inc. (CSE: PSYG | OTCQB: PSYGF) (“ Psyence ” or the “ Company ”) has successfully exported psilocybin mushrooms to Psilo Scientific Ltd. in Canada. Psilo Scientific, a wholly owned subsidiary o...
FILAMENT HEALTH AND ATMA JOURNEY CENTERS ANNOUNCE 14 SUBJECTS DOSED IN HEALTH CANADA-APPROVED PSILOCYBIN CLINICAL TRIAL Canada NewsWire Subjects were given Filament's psilocybin drug candidate in the first Canadian trial with the purpose of psychedelic therapist traini...
FILAMENT HEALTH APPOINTS NEW MEMBERS TO BOARD OF DIRECTORS AND ADVISORY COUNCIL Canada NewsWire VANCOUVER, BC , Aug. 24, 2022 /CNW/ - Filament Health Corp. (OTCQB: FLHLF) (NEO: FH) (FSE: 7QS) (" Filament " or the " Company "), a clinical...
FILAMENT HEALTH ANNOUNCES EIGHTH PATENT ISSUANCE Canada NewsWire The patent describes the extraction and standardization of stable doses of psychedelic compounds and strengthens Filament's industry-leading IP portfolio VANCOUVER, BC , Aug. 17, 2022 ...
FILAMENT HEALTH ANNOUNCES SECOND QUARTER 2022 FINANCIAL RESULTS AND OPERATIONAL HIGHLIGHTS Canada NewsWire VANCOUVER, BC , Aug. 15, 2022 /CNW/ - Filament Health Corp. (OTCQB: FLHLF) (NEO: FH) (FSE: 7QS) ("Filament" or the "Company"), a clinical-st...
FILAMENT HEALTH ANNOUNCES PARTICIPATION IN PROJECT SOLACE Canada NewsWire The newly-launched program, led by Canadian non-profit TheraPsil, is the world's largest medical psilocybin access and data project VANCOUVER, BC , July 28, 2022 /CNW/...
FILAMENT HEALTH ANNOUNCES CLOSING OF $2,500,080 PRIVATE PLACEMENT Canada NewsWire Financing led by psychedelic investment fund Negev Capital and leading functional mushroom manufacturer Nammex VANCOUVER, BC , July 13, 2022 /CNW/ - Filament Hea...
News, Short Squeeze, Breakout and More Instantly...
FILAMENT HEALTH CORP. Company Name:
FH:CC Stock Symbol:
AQNC Market:
FILAMENT HEALTH ANNOUNCES CLOSING OF WARRANT EXERCISE, NOTE CONVERSION AND CONCURRENT PRIVATE PLACEMENT OF COMMON SHARES Canada NewsWire VANCOUVER, BC , June 12, 2024 /CNW/ - Filament Health Corp. (OTCQB: FLHLF) (Cboe CA: FH) (FSE: 7QS) (" Filament " ...
FILAMENT HEALTH ANNOUNCES AUTHORIZATION OF PHASE 2 CLINICAL TRIAL FOR PEX010 IN THE TREATMENT OF METHAMPHETAMINE USE DISORDER Canada NewsWire Company study investigating PEX010, Filament's botanical psilocybin drug candidate, has been authorized by both FDA and Health Canada...
FILAMENT HEALTH ANNOUNCES WARRANT EXERCISE AND NOTE CONVERSION BY NEGEV CAPITAL AND CONCURRENT PRIVATE PLACEMENT OF COMMON SHARES TO BENJAMIN LIGHTBURN, CHIEF EXECUTIVE OFFICER Canada NewsWire VANCOUVER, BC , June 3, 2024 /CNW/ - Filament Health Corp. (OTCQB:...